Select license type

Please Select Linenece Type

Key Benefits

  • Consult directly with our domain leaders and get expert advice regarding the upcoming market.
  • Get the latest market insights and forecasts backed up by powerful research and statistical analysis
  • Customize the report as per your requirements and area of focus to avail great benefits for your business.

our clients
tiltle-brk

client-logo
client-logo2
client-logo3
client-logo4
client-logo
client-logo
client-logo
client-logo

"The quality of representation was outstanding. I never thought that understanding a complex market can be that much easy"

Adam Smith, Associate Director, Bain Capital

"More than just selling a report, the team was more focused towards the understanding of my requirements. Regular updation was the best part."

Koh Vivian, Product Development Manager, Swiss Bio Pharma

"Hats off to expert analysis, the team was very supporting and thanks for not charging me on additional data."

Erin Green, Director, Green Energy Consulting

" I really want to thank Goldstein Research for their efforts to make my project successful. F2F discussion with the market experts was excellent. Keep up the good work guyz "

Jorge Foyo, , Analyst, BCG
Market Research Report

Oncology/Cancer Biosimilars Market Report- By Product Type(Monoclonal Antibody, Immunomodulators), By Application(Cancer Treatment & Supportive Care Drugs), By Distribution Channel (Retail, Hospital, Online)

Published On : 2018-10-12 Report Page : 320 Category: Healthcare

Global Cancer/Oncology Biosimilars Market Analysis, 2017-2025

Market Highlights

A recent report on the market for cancer biosimilars published by Goldstein Research finds that it would grow at robust CAGR of 25.0% during 2017 and 2025. Large number of oncology biosimilars are in pipeline, and FDA has approved 4 biosimilars, 2 for cancer treatment and 2 for supportive care. Most recent was approved in June 2018 named Fulphila biosimilars to reduce the risk of infection during treatment of cancer. Fulphila is first biosimilar to Neulasta biologic manufactured by Amgen. Furthermore, the approval of delivery devices and formulation such as Neulasta Onpro Kit is providing competitive edge to the biologics from their biosimilars.

Our report also provide with qualitative information on the factors mentioned below:

  • Cancer Biosimilars market size and market compounded annual growth rate, 2017-2025
  • Oncology biosimilars in pipeline.
  • Sales and revenue of approved cancer biosimilars in market.
  • Cancer biosimilar in-house and contract manufacturing outlook.
  • Number of Oncology cases and growth rate of oncology cases, 2017-18.
  • What makes Amgen, Boehringer Ingelheim, Novartis, Biocon the major shareholders in Cancer biosimilars Market?

Key Players Mentioned In the Report

Amgen, Boehringer Ingelheim, Novartis, Biocon, Roche and many more.

Market Segmentation

Based on Product Type

  • Monoclonal Antibody
  • Immunomodulators
  • Others

Based on Application

  • Cancer Treatment Drugs
  • Supportive Care Drugs

Based on Distribution Channel 

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Based on Region

  • North America (U.S. & Canada)  Cancer/Oncology Biosimilars Market {Market Share (%), Market Size (USD Billion)}
  • Latin America (Brazil, Mexico, Argentina & Rest Of Latin America) Cancer/Oncology Biosimilars Market {Market Share (%), Market Size (USD Billion)}
  • Europe (The U.K., Germany, France, Italy, Hungary, Spain, Poland, Sweden & Roe)  Cancer/Oncology Biosimilars Market {Market Share (%), Market Size (USD Billion)}
  • Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest Of Asia) Cancer/Oncology Biosimilars Market {Market Share (%), Market Size (USD Billion)}
  • Middle East & Africa (GCC, South Africa, North Africa, Romea) Cancer/Oncology Biosimilars Market {Market Share (%), Market Size (USD Billion)}

North America Acquires Nearly 55% Share of Total Cancer/Oncology Biosimilars Market

Biosimilars are required to have identical route of administration, strength and dosage as the reference biologic. And the expiration date coming close to various cancer biologics will lead to approval of more biosimilars. However, US cost saving potential in manufacturing of biosimilar and value based case environment in the region tends to attract more number of biosimilars manufacturers willing to enter and expand their scope to oncology. Moreover, about 40% of prescription drugs spending in US is majorly on biologic drugs which is thus paving opportunities for biosimilars. The top pharmaceutical companies in US are intended to shift their focus on biosimilars as their approval is difficult compared to generic drugs, they better propositions for companies. 

Scope & Study Objectives Of This Report Are:

  • Ongoing and forecast period global cancer/oncology biosimilars market lookout in the developed and emerging markets
  • Analysis of the segment are expected to witness the fastest growth during the forecast period
  • To examine market competition scenario including expansions, product pipeline, generation capacity, material parameters, conveyance chain, agreements and merger acquisitions.
  • The local regulatory reforms, reimbursement and improvement strategies along with the forecast are clarified in each key point that indicates the general execution and issues in key areas, for example, the US, Asia Pacific, Middle East & Africa and Europe.

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements


Oncology/Cancer Biosimilars Market Report- By Product Type(Monoclonal Antibody, Immunomodulators), By Application(Cancer Treatment & Supportive Care Drugs), By Distribution Channel (Retail, Hospital, Online)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

OR Call Us:+1-646-568-7747